Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 11;7(2):e2094. doi: 10.1038/cddis.2016.11

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Combined treatment with PL and ZA synergistically inhibits cancer-induced osteoclastogenesis in vitro. (Aa) BMMs were treated with various concentrations of individual or combined PL and ZA plus RANKL for 5 days. TRAcP staining to elucidate osteoclast formation was performed in vitro. (b) The number and percentage of TRAcP-positive MNCs in the individual drug groups and the combination groups. (Ba) hPBMCs were treated with CM from MDA-MB-231 cells containing various concentrations of individual or combined PL and ZA for 21 days. TRAcP staining to elucidate osteoclast formation was performed in vitro. (b) The number and percentage of TRAcP-positive MNCs in the individual drug groups and the combination groups. The data are presented as the means±S.D. All experiments were repeated at least three times. Scale bar=250 μm (*significant difference at P<0.1; **significant difference at P<0.05)

Combined treatment with PL and ZA synergistically inhibits cancer-induced osteoclastogenesis in vitro. (Aa) BMMs were treated with various concentrations of individual or combined PL and ZA plus RANKL for 5 days. TRAcP staining to elucidate osteoclast formation was performed in vitro. (b) The number and percentage of TRAcP-positive MNCs in the individual drug groups and the combination groups. (Ba) hPBMCs were treated with CM from MDA-MB-231 cells containing various concentrations of individual or combined PL and ZA for 21 days. TRAcP staining to elucidate osteoclast formation was performed in vitro. (b) The number and percentage of TRAcP-positive MNCs in the individual drug groups and the combination groups. The data are presented as the means±S.D. All experiments were repeated at least three times. Scale bar=250 μm (*significant difference at P<0.1; **significant difference at P<0.05)